FDA clears Radionics' immobilisation device:
This article was originally published in Clinica
Executive Summary
Radionics has received US 510(k) marketing clearance for its device for immobilising and localising patients undergoing stereotactic radiation therapy treatments. The Body System device, which is used with Radionics' XPlan and IMRT (Intensity Modulated Radiation Therapy) treatment planning system, makes it possible to reproduce the set-up of the patient receiving fractionated treatments and align the radiation beam precisely to the tumour volume. This allows the tumour to be treated effectively while sparing the surrounding tissue, says the company, a division of Tyco Healthcare.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.